for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bicycle Therapeutics PLC (ADR)

BCYC.OQ

Latest Trade

27.60USD

Change

0.62(+2.30%)

Volume

2,031

Today's Range

27.00

 - 

27.60

52 Week Range

10.26

 - 

33.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
26.98
Open
27.00
Volume
2,031
3M AVG Volume
1.92
Today's High
27.60
Today's Low
27.00
52 Week High
33.00
52 Week Low
10.26
Shares Out (MIL)
21.30
Market Cap (MIL)
570.97
Forward P/E
-11.78
Dividend (Yield %)
--

Latest Developments

More

Bicycle Therapeutics Says BT7480 On Track For Phase I Trial Start In Second Half 2021

Bicycle Therapeutics Announces Settlement Of Patent Dispute With Pepscan Systems B.V.

Bicycle Therapeutics Files For ADSs Offering Of Up To $75 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bicycle Therapeutics PLC (ADR)

Bicycle Therapeutics PLC, formerly Bicycle Therapeutics Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The Company is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The Company is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.

Industry

Biotechnology & Drugs

Contact Info

Babraham Hall

CB22 3AT

United Kingdom

+44.1223.261503

https://www.bicycletherapeutics.com/

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-2.770

2020(E)

-2.275
Price To Earnings (TTM)
--
Price To Sales (TTM)
48.29
Price To Book (MRQ)
5.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.17
LT Debt To Equity (MRQ)
13.17
Return on Investment (TTM)
-29.19
Return on Equity (TTM)
-26.55

Latest News

Latest News

BRIEF-Physiomics Confirms Co Is In Late Stages Of Agreeing Contract With A Pharmaceutical Client

* PHYSIOMICS PLC - CONFIRM THAT IT IS IN LATE STAGES OF AGREEING A CONTRACT WITH POTENTIAL NEW LARGE PHARMACEUTICAL CLIENT Source text for Eikon: Further company coverage:

BRIEF-Bicycle Therapeutics Files For Mixed Shelf Of Upto $250 Million

* BICYCLE THERAPEUTICS FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: (https://bit.ly/2UeLZ4l) Further company coverage:

BRIEF-Bicycle Therapeutics Announces Pipeline Progress Update

* BICYCLE THERAPEUTICS PLC - PHASE I DOSE ESCALATION COMPLETED FOR BT1718-RP2D ESTABLISHED AND PRELIMINARY SIGNS OF ANTI-TUMOR ACTIVITY OBSERVED

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up